Glucocorticoids are universally used in the treatment of acute lymphoblastic leukemia (ALL),
and resistance to glucocorticoids in leukemia cells confers poor prognosis. To elucidate …

Hypersensitivity to asparaginase is common, but the differential diagnosis can be challenging
and the diagnostic utility of antibody tests is unclear. We studied allergic reactions and …

Glucocorticoids are important therapy for acute lymphoblastic leukemia (ALL) and their major
adverse effect is osteonecrosis. Our goal was to identify genetic and nongenetic risk factors …

Asparaginase is a therapeutic enzyme used to treat leukemia and lymphoma, with immune
responses resulting in suboptimal drug exposure and a greater risk of relapse. To elucidate …

Advances in pharmacogenetic testing will expand the number of clinically important
pharmacogenetic variants. Communication and interpretation of these test results are critical steps in …

We have previously hypothesized that higher systemic exposure to asparaginase may cause
increased exposure to dexamethasone, both critical chemotherapeutic agents for acute …

Asparaginase is used to treat acute lymphoblastic leukemia (ALL); however, hypersensitivity
reactions can lead to suboptimal asparaginase exposure. Our objective was to use a …

Osteonecrosis is a dose-limiting toxicity in the treatment of pediatric acute lymphoblastic
leukemia (ALL). Prior studies on the genetics of osteonecrosis have focused on patients ≥10 …

Combination of passive targeting with active targeting is a promising approach to improve the
therapeutic efficacy of nanotherapy. However, most reported polymeric systems have sizes …

Remission induction therapy for acute lymphoblastic leukemia (ALL) includes medications
that may cause hepatotoxicity, including asparaginase. We used a genome‐wide association …